AstraZaneca is a world leader in gastroenterology. For over three decades, the company has pioneered research in gastroenterology medicine, with a particular commitment to the treatment of acid-related diseases, beginning with the discovery of the proton pump indicator (PPI) class of drugs in 1974. The first PPI available for clinical use (omeprazole) in 1979, and now Nexium, the first PPI developed is an isomer. AstraZaneca has achieved
an evolution in PPI therapy beyond omeprazole and the other PPIs that followed.